<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="803">
  <stage>Registered</stage>
  <submitdate>10/09/2005</submitdate>
  <approvaldate>10/09/2005</approvaldate>
  <nctid>NCT00182364</nctid>
  <trial_identification>
    <studytitle>PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)</studytitle>
    <scientifictitle>PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FGMAEI-0042-048</secondaryid>
    <secondaryid>54618366 PROTECT pilot</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Critically Ill</healthcondition>
    <healthcondition>Deep Venous Thrombosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)

Treatment: drugs: Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome for the PROTECT Study is objectively confirmed proximal DVT (proven symptomatic or asymptomatic DVT) diagnosed by bilateral lower extremity compression ultrasound, confirmed by venography when possible.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>There are four secondary outcomes: 1) PE diagnosed by the PE Diagnosis algorithm, 2) bleeding, 3) anti-Xa levels associated with heparin dose adjustment, 4) thrombocytopenia and HIT</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Admission to ICU

          2. Men and women greater than 18 years of age or older

          3. Expected to remain in ICU admission greater than 72 hours</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Contraindications to LMWH or blood products

          2. Trauma, post orthopedic surgery, post cardiac surgery or post neurosurgery patients,

          3. Uncontrolled hypertension as defined by a systolic blood pressure &gt; 180 mmHg or a
             diastolic blood pressure &gt; 110 mmHg,

          4. Hemorrhagic stroke, DVT, PE or major hemorrhage on admission or within 3 months,

          5. Coagulopathy as defined by INR &gt;2 times upper limit of normal [ULN], or PTT &gt;2 times
             ULN,

          6. Renal insufficiency as defined by a creatinine clearance &lt;30ml/min,

          7. A need for oral or intravenous or subcutaneous therapeutic anticoagulation,

          8. Heparin allergy, proven or suspected heparin-induced thrombocytopenia (HIT),

          9. Receipt of &gt;2 doses of UFH or LMWH in ICU,

         10. Pregnant or lactating,

         11. Withdrawal of life support or limitation of life support,

         12. Prior enrollment in this trial

         13. Prior enrollment into a related RCT

         14. Thrombocytopenia defined platelet count &lt; 100 x 109/L,

         15. Bilateral lower limb amputation,

         16. Allergy to pork or pork products</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Alfred Hospital - Melbourne</hospital>
    <hospital>Royal North Shore Hospital of Sydney - Sydney</hospital>
    <postcode>3181 - Melbourne</postcode>
    <postcode>2065 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Hamilton Health Sciences Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Canadian Institutes of Health Research (CIHR)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Canadian Critical Care Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>PROTECT Pilot objective is to assess: 1) the feasibility of timely enrollment and complete,
      blinded study drug administration, 2) the bioaccumulation of LMWH in patients with acquired
      renal insufficiency and its association with bleeding, 3) the feasibility of scheduled twice
      weekly lower limb ultrasounds, and 4) recruitment rates for a future randomized trial.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00182364</trialwebsite>
    <publication>Clarke F, McDonald E, Rocker G, Cook DJ. Research coordinator activities in the ICU: An observational study. Abstract #108. Crit Care Med 2004;31(12)(suppl):A26.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Deborah J Cook, MD</name>
      <address>McMaster University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>